Risultati della ricerca - David Irwin

Raffina i risultati
  1. 1
    The Splenic Syndrome in Individuals with Sickle Cell Trait

    The Splenic Syndrome in Individuals with Sickle Cell Trait di Jessica Goodman, Kathryn Hassell, David Irwin, Ewa H. Witkowski, Rachelle Nuss

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    RhoGTPase in Vascular Disease

    RhoGTPase in Vascular Disease di Derek Strassheim, Evgenia Gerasimovskaya, David Irwin, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer

    Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer di Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus, David Irwin, James L. Speyer, Alan J. Koletsky, Paula Klein, Tariq Sabir, Lori Kronish

    Pubblicazione 2002
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    A Single-Center Experience with a Shear-Thinning Conformable Embolic

    A Single-Center Experience with a Shear-Thinning Conformable Embolic di Koustav Pal, Milan Patel, Stephen Chen, Bruno C. Odisio, Zeyad Metwalli, Judy U. Ahrar, David Irwin, Rahul A. Sheth, J. Kuban

    Pubblicazione 2024
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease

    Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease di Ayla Yalamanoglu, Jeremy W. Deuel, Ryan Hunt, Jin Hyen Baek, Kathryn L. Hassell, Katie Redinius, David Irwin, Dominik J. Schaer, Paul W. Buehler

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Nrf2 activation: A potential strategy for the prevention of acute mountain sickness

    Nrf2 activation: A potential strategy for the prevention of acute mountain sickness di Christina Lisk, Joe M. McCord, Swapan K. Bose, Timothy J. Sullivan, Zoe Loomis, Eva Nozik‐Grayck, Thies Schroeder, Karyn L. Hamilton, David Irwin

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration

    Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dos... di David Irwin, Jin Hyen Baek, Kathryn L. Hassell, Rachelle Nuss, Paul Eigenberger, Christina Lisk, Zoe Loomis, Joanne Maltzahn, Kurt R. Stenmark, Eva Nozik‐Grayck, Paul W. Buehler

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

    Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma di Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Eli Gabayan, Amitabha Mazumder, David P. Schenkein, John Crowley

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

    Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma di Paul G. Richardson, Bart Barlogie, James R. Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David P. Schenkein, Kenneth C. Anderson

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

    Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study di Stephanie J. Lee, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Jesús F. San Miguel, Bruce Crawford, Joseph M. Massaro, Ravinder Dhawan, Sanjay Gupta, Kenneth C. Anderson

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism

    Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism di Paul W. Buehler, Jin Hyen Baek, Christina Lisk, Ian Connor, Timothy J. Sullivan, Douglas J. Kominsky, Susan M. Majka, Kurt R. Stenmark, Eva Nozik‐Grayck, J. Bonaventura, David Irwin

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

    Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma di Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension

    Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension di Douglas D. Lemon, Todd R. Horn, Maria A. Cavasin, Mark Y. Jeong, Kurt Haubold, Carlin S. Long, David Irwin, Sylvia A. McCune, Eunhee Chung, Leslie A. Leinwand, Timothy A. McKinsey

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

    Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial di Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning, M. Biakhov, David Irwin, Norbert Marschner, C. Slabber, George Fountzilas, A. Garin, N.G.F. Abecasis, W. Baronius, G. Steger, T Südhoff, C. Giorgetti, Peter Reichardt

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

    Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma di Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Jesús F. San Miguel, Jamie Cavenagh, Kenneth C. Anderson

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension

    Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension di Eva Nozik‐Grayck, Crystal Woods, Joann M. Taylor, Richard K.P. Benninger, R. Daniel Johnson, Leah R. Villegas, Kurt R. Stenmark, David G. Harrison, Susan M. Majka, David Irwin, Kathryn N. Farrow

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma di Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Rubén Niesvizky, Raymond Alexanian, Steven Limentani, Melissa Alsina, Julian Adams, Michael Kauffman, Dixie‐Lee Esseltine, David P. Schenkein, Kenneth C. Anderson

    Pubblicazione 2004
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

    The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multip... di Rubén Niesvizky, Paul G. Richardson, S. Vincent Rajkumar, Morton Coleman, Laura Rosiñol, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Anthony Boral, Dixie‐Lee Esseltine, Kenneth C. Anderson, Joan Bladé

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak

    A potential role for reactive oxygen species and the HIF-1α–VEGF pathway in hypoxia-induced pulmonary vascular leak di David Irwin, Joe M. McCord, Eva Nozik‐Grayck, Ginny Beckly, Ben Foreman, Timothy J. Sullivan, Molly White, Joseph T. Crossno, Damian M. Bailey, Sonia C. Flores, Susan M. Majka, Dwight J. Klemm, Martha C. Tissot van Patot

    Pubblicazione 2009
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

    Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma di Paul G. Richardson, Sundar Jagannath, Mohamad A. Hussein, James R. Berenson, Seema Singhal, David Irwin, Stephanie Williams, William Bensinger, Ashraf Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Kenneth C. Anderson

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: